Design and evaluation of novel 4-anilinoquinolines and quinazolines as EGFR inhibitors in lung cancer and chordoma
C. R. M. Asquith, K. A. Maffuid, T. Laitinen, C. D. Torrice, G. J. Tizzard, C. Alamillo-Ferrer, K. M. Koshlap, D. J. Crona, W. Zuercher
The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.
bioRxiv · Feb 11, 2019 · PreprintPharmacology & Toxicology